Chun-Liang Wang

Dr. Chun-Liang Wang

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 November 2014 in Asian Pacific Journal of Cancer Prevention
Verified
Journal Article
Open access
PDF file
YLYuan-Yuan Lei
Yuan-Yuan Lei
WWWei-Jia Wang
Wei-Jia Wang
JMJinhong Mei
Jinhong Mei
CWChun-Liang Wang
Chun-Liang Wang
Mitogen-Activated Protein Kinase Signal Transduction in Solid Tumors MAPK;mechanisms of action;tumor development;treatment; Mitogen-activated protein kinase (MAPK) is an important signaling pathway in living beings in response to extracellular stimuli. There are 5 main subgroups manipulating by a set of sequential actions: ERK(ERK1/ERK2), c-Jun N(JNK/SAPK), p38 MAPK($p38{\alpha}$, $p38{\beta}$, $p38{\gamma}$ and $p38{\delta}$), and ERK3/ERK4/ERK5. When stimulated, factors of upstream or downstream change, and by interacting with each other, these groups have long been recognized to be related to multiple biologic processes such as cell proliferation, differentiation, death, migration, invasion and inflammation. However, once abnormally activated, cancer may occur. Several components of the MAPK network have already been proposed as targets in cancer therapy, such as p38, JNK, ERK, MEK, RAF, RAS, and DUSP1. Among them, alteration of the RAS-RAF-MEK-ERK-MAPK(RAS-MAPK) pathway has frequently been reported in human cancer as a result of abnormal activation of receptor tyrosine kinases or gain-of-function mutations in genes. The reported roles of MAPK signaling in apoptotic cell death are controversial, so that further in-depth investigations are needed to address these controversies. Based on an extensive analysis of published data, the goal of this review is to provide an overview on recent studies about the mechanism of MAP kinases, and how it generates certain tumors, as well as related treatments.

9 October 2021 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Closed access
PDF file
SLShaoYang Li
ShaoYang Li
LYLe Yang
Le Yang
ZTZhiGao Tong
ZhiGao Tong
BWBoWen Wu
BoWen Wu
BTBin Tang
Bin Tang
HTHong Tao
Hong Tao

11 August 2022 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Closed access
PDF file
GLgang liao
gang liao
MZMeimei Zhang
Meimei Zhang
CWChun-Liang Wang
Chun-Liang Wang

12 May 2022 in Research Square
Verified
Preprint
Open access
PDF file
GLGang Liao
Gang Liao
MZMeimei Zhang
Meimei Zhang
CWChun-Liang Wang
Chun-Liang Wang
Background:Glioma is the most common primary intracranial tumor. It is notorious for its high degree of malignancy, strong invasion, and poor prognosis. The transmembrane emp24 trafficking protein 3 (TMED3) belongs to the TMED family, which is responsible for intracellular protein transport and innate immune signal transmission. More and more evidence shows that TMED3 plays a key role in the tumor progression of human cancer. However, the role and potential molecular mechanism of TMED3 in glioma have not been clarified. Methods: TMED3 expression levels, clinical data, survival prognosis, prediction of upstream miRNA, and immune-related analyses were all analyzed utilizing relevant databases. Finally, a molecular cell experiment confirmed TMED3 expression in glioma. Results: We discovered that TMED3 is overexpressed in most tumors, including gliomas, and is associated with tumor staging and prognosis. Subsequently, a combination of a series of bioinformatics analyses, including correlation and survival analyses, identified miR-1296-5p as the most potent upstream miRNA of TMED3 in gliomas.Additionally, we analyzed the relationship between TMED3 level and tumor immune cell infiltration and immune checkpoint expression.Conclusion TMED3 is highly expressed in gliomas and is associated with tumor staging and affects the prognosis of patients. Therefore, the TMED3 gene may be a potential immunotherapy target and prognostic marker for gliomas.

6 January 2023 in Frontiers in Surgery
Verified
Journal Article
Open access
GLGang Liao
Gang Liao
KCKang Chen
Kang Chen
JXJiang Xu
Jiang Xu
CWChun-Liang Wang
Chun-Liang Wang
Background: In recent years, some cases of rhabdomyolysis after surgery have been reported. In this report, we present an adult patient with rhabdomyolysis after intracranial aneurysm surgery.Case Report: A 59-year-old male suffered from a coma, fever, and soy sauce urine after intracranial aneurysm clipping. A routine blood examination showed that liver and kidney function were impaired, and creatine phosphokinase(CK) and creatine phosphokinase isoenzyme(CK-MB) levels increased. Therefore, we consider patients with rhabdomyolysis after intracranial aneurysm surgery. A series of treatment schemes, such as intravenous fluid infusion, alkalized urine, and hemodialysis, were adopted immediately, and finally the patient was discharged safely.Conclusion: For some postoperative patients, once the level of CK/CK-MB increases, acute renal damage occurs, and the urine color turns soy sauce, we should be alert to postoperative rhabdomyolysis.For those patients who have been diagnosed with rhabdomyolysis, we need to take timely treatment measures to avoid an unfortunate occurrence.

2 December 2021 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Closed access
PDF file
SLShaoYang Li
ShaoYang Li
LYLe Yang
Le Yang
ZTZhiGao Tong
ZhiGao Tong
BWBoWen Wu
BoWen Wu
BTBin Tang
Bin Tang
HTHong Tao
Hong Tao